Resonance shared a post on LinkedIn:
“Join us this upcoming Thursday, March 26th (0830EST/1430CET) for this special session where Dr. Gabriela Villanueva will be joining us to discuss this recent publication:
“Latin American Consensus on the Use of Anti-GD2 Monoclonal Antibody Therapy in Patients With High-Risk Neuroblastoma“.
Gabriela Villanueva, MD, MS is a pediatric hematologist and oncologist at Hospital de Clínicas José de San Martín, Argentina, and the Director of Academic Affairs at Resonance Health.
We look forward to learning together in what will be an excellent discussion.”
Other articles featuring Resonance on OncoDaily.